NA 931
Alternative Names: NA-931Latest Information Update: 20 Mar 2024
At a glance
- Originator Biomed Industries
- Class Neuroprotectants; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists; Insulin secretion stimulants; Insulin-like growth factor I stimulants; Insulinotropin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity